{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:08:25Z","timestamp":1788854905603,"version":"build-2803163510"},"reference-count":81,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR133443"],"award-info":[{"award-number":["NIHR133443"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronavirus disease-2019 was associated with significant mortality and morbidity in care homes in 2020\u20131. Repurposed antiviral drugs might reduce morbidity and mortality through reducing viral transmission, infection, replication and inflammation. We aimed to compare the safety and efficacy of potential antiviral drugs in care home residents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We designed a cluster-randomised, open-label, blinded end-point platform trial to test drugs in a postexposure prophylaxis paradigm. Participants aged 65+\u2005years from United Kingdom care homes, with or without nursing, were eligible for participation. Care homes were to be allocated at random by computer to administer 42 days of antiviral agent (ciclesonide or niclosamide) plus standard care versus standard care alone to residents. The primary outcome at 60 days after randomisation comprised the most serious outcome, which was defined as all-cause mortality, all-cause hospitalisation, severe acute respiratory syndrome coronavirus 2 infection or no infection. Analysis would be by intention to treat using ordinal logistic regression. Other outcomes included individual components of the primary outcome, transmission, plus health economic and process evaluation outcomes. The planned sample size was 300 care homes corresponding to 9600 residents. With ~40% of care homes predicted to develop an outbreak during the trial, we needed to recruit 750 homes\/24,000 residents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We initiated the trial including protocol, approvals, insurance, website, database, data algorithms, intervention selection and training materials. We built a network of principal investigators and staff (91) and care homes (299) to support the trial. However, we never contracted care homes or general practitioners since the trial was stopped in September 2021, as vaccination in care homes had significantly reduced infections. Multiple delays significantly delayed the start date, such as: (1) reduced prioritisation of pandemic trials in 2021; (2) cumbersome mechanisms for choosing the investigational medicinal products; (3) contracting between National Institute for Health and Care Research and the investigational medicinal product manufacturers; (4) publicising the investigational medicinal products; (5) identification of sufficient numbers of care homes; (6) identification and contracting with several thousand general practitioners; (7) limited research nurse availability and (8) identification of adequate insurance to cover care homes for research. Generic challenges included working across the four home nations with their different structures and regulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>The feasibility of contracting between the sponsor and the principal investigators, general practitioners and care homes; screening, consent and treatment of care home residents; data acquisition and the potential benefit of postexposure prophylaxis were never tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The success of vaccination meant that the role of postexposure prophylaxis of coronavirus disease-2019 in care home residents was not tested. Significant progress was made in developing the infrastructure and expertise necessary for a large-scale clinical trial of investigational medicinal products in United Kingdom care homes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Future work<\/jats:title>\n                    <jats:p>The role of postexposure prophylaxis of coronavirus disease-2019 in care home residents remains undefined. Significant logistical barriers to conducting research in care homes need to be removed urgently before future studies are possible. Further work is required to develop the infrastructure for clinical trials of investigational medicinal products in care homes. Serious consideration should be given to building and then hibernating a pandemic-ready platform trial suitable for care home research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR133443.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/mtrs8833","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T03:58:16Z","timestamp":1731988696000},"page":"1-26","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Lessons from the PROTECT-CH COVID-19 platform trial in care homes"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-5132","authenticated-orcid":true,"given":"Philip M","family":"Bath","sequence":"first","affiliation":[{"name":"Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-8733","authenticated-orcid":true,"given":"Jonathan","family":"Ball","sequence":"additional","affiliation":[{"name":"Infections, Immunity and Microbes, School of Life Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-5090","authenticated-orcid":true,"given":"Matthew","family":"Boyd","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Policy, School of Pharmacy, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-9406","authenticated-orcid":true,"given":"Heather","family":"Gage","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Surrey Health Economics Centre, University of Surrey, Guildford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-2668","authenticated-orcid":true,"given":"Matthew","family":"Glover","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Surrey Health Economics Centre, University of Surrey, Guildford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Godfrey","sequence":"additional","affiliation":[{"name":"c\/o Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-4880","authenticated-orcid":true,"given":"Bruce","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Advanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-1792","authenticated-orcid":true,"given":"Jonathan","family":"Hewitt","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-2338","authenticated-orcid":true,"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-188X","authenticated-orcid":true,"given":"Thomas","family":"Jaki","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-2247","authenticated-orcid":true,"given":"Edmund","family":"Juszczak","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-5580","authenticated-orcid":true,"given":"Daniel","family":"Lasserson","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-0274","authenticated-orcid":true,"given":"Paul","family":"Leighton","sequence":"additional","affiliation":[{"name":"Lifespan and Population Sciences, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Leyland","sequence":"additional","affiliation":[{"name":"Bramcote, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-3051","authenticated-orcid":true,"given":"Wei","family":"Shen Lim","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-2381","authenticated-orcid":true,"given":"Pip","family":"Logan","sequence":"additional","affiliation":[{"name":"Unit of Injury, Inflammation and Recovery, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8593-3421","authenticated-orcid":true,"given":"Garry","family":"Meakin","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-1606","authenticated-orcid":true,"given":"Alan","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-4117","authenticated-orcid":true,"given":"Reuben","family":"Ogollah","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-5509","authenticated-orcid":true,"given":"Peter","family":"Passmore","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Institute for Clinical Sciences, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3012-6646","authenticated-orcid":true,"given":"Philip","family":"Quinlan","sequence":"additional","affiliation":[{"name":"Digital Health & Digital Research Service, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-9834","authenticated-orcid":true,"given":"Caroline","family":"Rick","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-6036","authenticated-orcid":true,"given":"Simon","family":"Royal","sequence":"additional","affiliation":[{"name":"University of Nottingham Health Service, Cripps Health Centre, University Park, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7375-4776","authenticated-orcid":true,"given":"Susan D","family":"Shenkin","sequence":"additional","affiliation":[{"name":"Advanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-6315","authenticated-orcid":true,"given":"Clare","family":"Upton","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1676-9853","authenticated-orcid":true,"given":"Adam L","family":"Gordon","sequence":"additional","affiliation":[{"name":"NIHR Applied Research Collaboration-East Midlands (ARC-EM), Institute of Mental Health, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,4]]},"reference":[{"key":"key2026090807045500_ref1-bib1","first-page":"2022","article-title":"Prophylactic treatment of COVID-19 in care homes trial (PROTECT-CH)","author":"Bath","year":"2022","journal-title":"medRxiv"},{"key":"key2026090807045500_ref2-bib2","volume-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)","author":"Center for Systems Science and Engineering","year":"2021"},{"key":"key2026090807045500_ref3-bib3","volume-title":"Number of Deaths in Care Homes Notified to the Care Quality Commission, England","author":"Office of National Statistics","year":"2020"},{"key":"key2026090807045500_ref4-bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ageing\/afab080","article-title":"Impact of COVID-19 on care-home mortality and life expectancy in Scotland","volume":"50","author":"Burton","year":"2021","journal-title":"Age Ageing"},{"key":"key2026090807045500_ref5-bib5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref6-bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"key2026090807045500_ref7-bib7","first-page":"2021","article-title":"Molnupiravir, an oral antiviral treatment for COVID-19","author":"Fischer","year":"2021","journal-title":"medRxiv"},{"key":"key2026090807045500_ref8-bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref9-bib9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14787210.2023.2241638","article-title":"Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19","volume":"21","author":"Navitha Reddy","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key2026090807045500_ref10-bib10","doi-asserted-by":"crossref","first-page":"e28889","DOI":"10.1002\/jmv.28889","article-title":"Comparative efficacy and safety of nirmatrelvir\/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J Med Virol"},{"key":"key2026090807045500_ref11-bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref12-bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Recovery Collaborative Group","year":"2020","journal-title":"Lancet"},{"key":"key2026090807045500_ref13-bib13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"key2026090807045500_ref14-bib14","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with COVID-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref15-bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref16-bib16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Recovery Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"key2026090807045500_ref17-bib17","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref18-bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Recovery Collaborative Group","year":"2022","journal-title":"Lancet"},{"key":"key2026090807045500_ref19-bib19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref20-bib20","first-page":"665","article-title":"Recovery Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with covid-19 (recovery): a randomised, controlled, open-label, platform trial","volume":"399","author":"Horby","year":"2022"},{"key":"key2026090807045500_ref21-bib21","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Recovery Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"key2026090807045500_ref22-bib22","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026090807045500_ref23-bib23","first-page":"2021","article-title":"Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial","author":"Yu","year":"2021","journal-title":"medRxiv"},{"key":"key2026090807045500_ref24-bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","article-title":"Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Recovery Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"key2026090807045500_ref25-bib25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"key2026090807045500_ref26-bib26","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"key2026090807045500_ref27-bib27","doi-asserted-by":"crossref","first-page":"afac052","DOI":"10.1093\/ageing\/afac052","article-title":"The COVID-19 pandemic has highlighted the need to invest in care home research infrastructure","volume":"51","author":"Gordon","year":"2022","journal-title":"Age Ageing"},{"key":"key2026090807045500_ref28-bib28","article-title":"Inhaled corticosteroids for the treatment of COVID-19","volume":"3","author":"Griesel","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090807045500_ref29-bib29","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1111\/bph.15843","article-title":"Niclosamide \u2013 a promising treatment for COVID-19","volume":"179","author":"Singh","year":"2022","journal-title":"Br J Pharmacol"},{"key":"key2026090807045500_ref31-bib31","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.eclinm.2020.100403","article-title":"Endpoints used in phase III randomized controlled trials of treatment options for COVID-19","volume":"23","author":"Desai","year":"2020","journal-title":"EClinicalMedicine"},{"key":"key2026090807045500_ref32-bib32","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1161\/STROKEAHA.108.527044","article-title":"Ordinal reanalysis of the SHEP trial","volume":"39","author":"Bath","year":"2008","journal-title":"Stroke"},{"key":"key2026090807045500_ref33-bib33","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1161\/STROKEAHA.107.509893","article-title":"Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published stroke trials","volume":"39","author":"Bath","year":"2008","journal-title":"Stroke"},{"key":"key2026090807045500_ref34-bib34","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/eurheartj\/ehn299","article-title":"Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta analysis","volume":"29","author":"Sare","year":"2008","journal-title":"Eur Heart J"},{"key":"key2026090807045500_ref35-bib35","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1161\/STROKEAHA.106.474080","article-title":"Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials","volume":"38","author":"Bath","year":"2007","journal-title":"Stroke"},{"key":"key2026090807045500_ref36-bib36","doi-asserted-by":"crossref","first-page":"e5661","DOI":"10.1136\/bmj.e5661","article-title":"2010 statement: extension to cluster randomised trials","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"key2026090807045500_ref37-bib37","doi-asserted-by":"crossref","first-page":"m115","DOI":"10.1136\/bmj.m115","article-title":"The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"BMJ"},{"key":"key2026090807045500_ref38-bib38","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1161\/STROKEAHA.107.509893","article-title":"Optimising the analysis of stroke prevention trials: converting dichotomous vascular outcomes into ordinal measures","volume":"39","author":"Bath","year":"2008","journal-title":"Stroke"},{"key":"key2026090807045500_ref39-bib39","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/STROKEAHA.111.641456","article-title":"Statistical analysis of the primary outcome in acute stroke trials","volume":"43","author":"Bath","year":"2012","journal-title":"Stroke"},{"key":"key2026090807045500_ref40-bib40","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/sim.4780122404","article-title":"Sample-size calculations for ordered categorical-data","volume":"12","author":"Whitehead","year":"1993","journal-title":"Stat Med"},{"key":"key2026090807045500_ref41-bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1747-4949.2008.00184.x","article-title":"Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches","volume":"3","author":"The Optimising Analysis of Stroke Trials (OAST) Collaboration","year":"2008","journal-title":"Int J Stroke"},{"key":"key2026090807045500_ref42-bib42","unstructured":"Competition & Markets Authority. Care homes market study final report. 30 November 2017."},{"key":"key2026090807045500_ref43-bib43","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2666-7568(20)30012-X","article-title":"Evolution and effects of COVID-19 outbreaks in care homes: a population analysis in 189 care homes in one geographical region of the UK","volume":"1","author":"Burton","year":"2020","journal-title":"Lancet Healthy Longev"},{"key":"key2026090807045500_ref44-bib44","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/ije\/dyl129","article-title":"Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method","volume":"35","author":"Eldridge","year":"2006","journal-title":"Int J Epidemiol"},{"key":"key2026090807045500_ref45-bib45","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1002\/(SICI)1097-0258(19991230)18:24<3435::AID-SIM365>3.0.CO;2-O","article-title":"The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials","volume":"18","author":"Buyse","year":"1999","journal-title":"Stat Med"},{"key":"key2026090807045500_ref46-bib46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/01410768211041245","article-title":"The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic","volume":"114","author":"Glasziou","year":"2021","journal-title":"J R Soc Med"},{"key":"key2026090807045500_ref47-bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"key":"key2026090807045500_ref48-bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","article-title":"An overview of platform trials with a checklist for clinical readers","volume":"125","author":"Park","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"key2026090807045500_ref49-bib49","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"key2026090807045500_ref50-bib50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"key2026090807045500_ref51-bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12874-020-00925-z","article-title":"Contamination in complex healthcare trials: the falls in care homes (FinCH) study experience","volume":"20","author":"Robinson","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"key2026090807045500_ref52-bib52","author":"Shackleton","year":"1988"},{"key":"key2026090807045500_ref53-bib53","doi-asserted-by":"crossref","first-page":"ckac129","DOI":"10.1093\/eurpub\/ckac129.751","article-title":"Establishing COVID-19 research in UK care homes \u2013 infrastructure challenges for trial design","volume":"32","author":"Leighton","year":"2022","journal-title":"Eur J Public Health"},{"key":"key2026090807045500_ref54-bib54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13063-023-07128-z","article-title":"PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)","volume":"24","author":"Humphrey","year":"2023","journal-title":"Trials"},{"key":"key2026090807045500_ref55-bib55","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s41999-022-00714-5","article-title":"Dietary nitrate supplementation for preventing and reducing the severity of winter infections, including COVID-19, in care homes (BEET-Winter): a randomised placebo-controlled feasibility trial","volume":"13","author":"Bath","year":"2022","journal-title":"Eur Geriatr Med"},{"key":"key2026090807045500_ref56-bib56","volume-title":"COVID-19 Response Identifying a Clinical Lead for All Care Homes 12 May 2020","author":"Kanani","year":"2020"},{"key":"key2026090807045500_ref58-bib58","doi-asserted-by":"crossref","first-page":"536","DOI":"10.12688\/f1000research.51270.2","article-title":"Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections","volume":"10","author":"Bath","year":"2021","journal-title":"F1000Res"},{"key":"key2026090807045500_ref59-bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19160","article-title":"Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial \u2018in hibernation\u2019, ready for rapid activation","volume":"19","author":"Lim","year":"2015","journal-title":"Health Technol Assess"},{"key":"key2026090807045500_ref60-bib60","author":"Hallett","year":"2024"},{"key":"key2026090807045500_ref61-bib61","doi-asserted-by":"crossref","first-page":"e0294872","DOI":"10.1371\/journal.pone.0294872","article-title":"Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: a living review and meta-analysis","volume":"18","author":"Yu","year":"2023","journal-title":"PLOS ONE"},{"key":"key2026090807045500_ref62-bib62","volume-title":"PROTECT-V Study Stepped up in Fight against COVID","author":"Smith","year":"2023"},{"key":"key2026090807045500_ref63-bib63","doi-asserted-by":"crossref","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key2026090807045500_ref64-bib64","first-page":"25","article-title":"Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma","volume":"2","author":"Schaffner","year":"2009","journal-title":"J Asthma Allergy"},{"key":"key2026090807045500_ref65-bib65","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.rmed.2010.09.016","article-title":"Efficacy and safety of ciclesonide in the treatment of 24,037 asthmatic patients in routine medical care","volume":"105","author":"Vogelmeier","year":"2011","journal-title":"Respir Med"},{"key":"key2026090807045500_ref66-bib66","doi-asserted-by":"crossref","first-page":"14013","DOI":"10.1038\/npjpcrm.2014.13","article-title":"The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?","volume":"24","author":"van der Molen","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"key2026090807045500_ref67-bib67","doi-asserted-by":"crossref","first-page":"e01648","DOI":"10.1128\/JVI.01648-20","article-title":"The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells","volume":"95","author":"Matsuyama","year":"2020","journal-title":"J Virol"},{"key":"key2026090807045500_ref68-bib68","doi-asserted-by":"crossref","first-page":"198089","DOI":"10.1016\/j.virusres.2020.198089","article-title":"The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide","volume":"290","author":"Yamasaki","year":"2020","journal-title":"Virus Res"},{"key":"key2026090807045500_ref69-bib69","doi-asserted-by":"crossref","first-page":"2001009","DOI":"10.1183\/13993003.01009-2020","article-title":"Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective","volume":"55","author":"Halpin","year":"2020","journal-title":"Eur Respir J"},{"key":"key2026090807045500_ref70-bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jmii.2020.09.003","article-title":"Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia","volume":"54","author":"Mori","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"key2026090807045500_ref71-bib71","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/ggi.14034","article-title":"COVID-19 in older adults: retrospective cohort study in a tertiary hospital in Japan","volume":"20","author":"Sano","year":"2020","journal-title":"Geriatr Gerontol Int"},{"key":"key2026090807045500_ref72-bib72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5582\/ddt.2022.01068","article-title":"Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: a randomized trial","volume":"16","author":"Terada-Hirashima","year":"2022","journal-title":"Drug Discov Ther"},{"key":"key2026090807045500_ref73-bib73","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cmi.2022.02.031","article-title":"Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)","volume":"28","author":"Duvignaud","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"key2026090807045500_ref74-bib74","doi-asserted-by":"crossref","first-page":"e064374","DOI":"10.1136\/bmjopen-2022-064374","article-title":"Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19)","volume":"13","author":"Brodin","year":"2023","journal-title":"BMJ Open"},{"key":"key2026090807045500_ref75-bib75","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.eclinm.2022.101484","article-title":"Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with\/without oxygen therapy: an open-label, single-center phase 3 randomized clinical trial","volume":"49","author":"Terada","year":"2022","journal-title":"EClinicalMedicine"},{"key":"key2026090807045500_ref76-bib76","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jmii.2023.07.008","article-title":"Inhaled corticosteroid for patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"56","author":"Hsu","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"key2026090807045500_ref77-bib77","first-page":"2020","article-title":"Broad-spectrum, patient-adaptable inhaled niclosamide-lysozyme particles are efficacious against coronaviruses in lethal murine infection models","author":"Brunaugh","year":"2020","journal-title":"bioRxiv"},{"key":"key2026090807045500_ref78-bib78","doi-asserted-by":"crossref","first-page":"100084","DOI":"10.1016\/j.lanepe.2021.100084","article-title":"A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: a broad spectrum antiviral candidate for treatment of COVID-19","volume":"4","author":"Backer","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"key2026090807045500_ref79-bib79","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.amsu.2021.102779","article-title":"A randomised controlled trial of effectiveness and safety of niclosamide as add on therapy to the standard of care measures in COVID-19 management","volume":"69","author":"Abdulamir","year":"2021","journal-title":"Ann Med Surg"},{"key":"key2026090807045500_ref80-bib80","volume-title":"Realistic Evaluation","author":"Pawson","year":"1997"},{"key":"key2026090807045500_ref81-bib81","doi-asserted-by":"crossref","DOI":"10.4135\/9781849209120","volume-title":"Evidence Based Policy: A Realist Perspective","author":"Pawson","year":"2006"},{"key":"key2026090807045500_ref82-bib82","volume-title":"Mind the Gap: Evaluation and the Disciplines","author":"Pawson","year":"2010"},{"key":"key2026090807045500_ref83-bib83","doi-asserted-by":"crossref","DOI":"10.4135\/9781526451729","volume-title":"Doing Realist Research","author":"Emmel","year":"2018"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/MTRS8833\/MTRS8833.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:37:24Z","timestamp":1788853044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/MTRS8833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":81,"alternative-id":["10.3310\/MTRS8833"],"URL":"https:\/\/doi.org\/10.3310\/mtrs8833","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"01-2021","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"11-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}